The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.
 
Masayuki Shirasawa
No Relationships to Disclose
 
Tatsuya Yoshida
Speakers' Bureau - Archer; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai/Roche; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Yukiko Shimoda
No Relationships to Disclose
 
Daisuke Takayanagi
No Relationships to Disclose
 
Kouya Shiraishi
No Relationships to Disclose
 
Takashi Kubo
Consulting or Advisory Role - Sysmex
 
Sachiyo Mitani
No Relationships to Disclose
 
Yuji Matsumoto
Honoraria - AMCO; AstraZeneca; Cook Medical; Novartis; Olympus Medical Systems
Research Funding - Grant-in-Aid for Scientific Research on Innovative Areas (Inst); Hitachi (Inst); Hitachi Chemical (Inst); National Cancer Center (Inst)
 
Ken Masuda
Honoraria - Chugai Pharma
 
Yuki Shinno
Speakers' Bureau - Chugai Pharma
 
Yusuke Okuma
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Lilly
Research Funding - Abbvie (Inst); Chugai Pharma (Inst)
 
Yasushi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Guardant Health AMEA; Illumina; Kyorin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Kyorin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hidehito Horinouchi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD Oncology; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; MSD Oncology; Novartis
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); BMKK (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genomic Health (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hitoshi Ichikawa
Research Funding - Chugai Pharma (Inst); Eisai (Inst); Healios (Inst); Ono Pharmaceutical (Inst)
 
Takashi Kohno
Consulting or Advisory Role - Lilly Japan; Loxo
Research Funding - Daiichi Sankyo; Sysmex
 
Noboru Yamamoto
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Pfizer; Sysmex
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shun-ichi Watanabe
No Relationships to Disclose
 
Noriko Motoi
Honoraria - AstraZeneca; Becton Dickinson; Chugai Pharma; Covidien; MSD; Novartis
Research Funding - NEC Corporation (Inst); Ono Pharmaceutical (Inst)
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Lilly Japan (Inst); LOXO (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)